CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 28, 2019	Sep. 29, 2018
Cash Flows from Operating Activities:
Net income	$ 29,007	$ 15,907
Non-cash items:
Depreciation and amortization	54,469	51,692
Impairment of assets	48,721	21,170
Share-based compensation expense	9,730	7,961
Deferred tax benefit	(7,290)	0
Provision for losses on accounts receivable and inventory	(1,857)	549
Gain on sale of assets	(8,083)	0
Other non-cash operating activities	140	1,277
Change in operating assets and liabilities:
Change in accounts receivable	7,806	(13,326)
Change in inventories	(59,439)	(3,912)
Change in other assets and other liabilities	(12,204)	3,746
Change in accounts payable and accrued expenses	(28,471)	(4,585)
Net cash provided by operating activities	32,529	80,479
Cash Flows from Investing Activities:
Capital expenditures	(17,722)	(76,002)
Proceeds from divestiture	9,808	0
Proceeds from sale of property, plant and equipment	15,739	656
Net cash provided by (used in) investing activities	7,825	(75,346)
Cash Flows from Financing Activities:
Net increase in short-term loans	25,000	0
Term loan borrowings	0	347,780
Repayment of term loan borrowings	(4,375)	(258,103)
Other	72	0
Proceeds from employee stock purchase plan	1,830	1,780
Proceeds from exercise of stock options	6,046	7,127
Share repurchases	(125,000)	(80,000)
Net cash (used in) provided by financing activities	(96,427)	18,584
Effect of exchange rates on cash and cash equivalents	(1,248)	(4,123)
Net Change in Cash and Cash Equivalents	(57,321)	19,594
Cash and Cash Equivalents at Beginning of Period	169,351	180,169
Cash and Cash Equivalents at End of Period	112,030	199,763
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,260	5,833
Income taxes paid	8,535	5,053
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 5,780	$ 12,099